** Shares of drugmaker Vertex Pharmaceuticals VRTX.O rise 1.6% to $452.55
** VRTX says its cystic fibrosis treatment, Alyftrek, receives European Commission approval in patients 6 years and older in EU
** Cystic fibrosis is an inherited disorder resulting from the absence of a specific protein, which disrupts the movement of salt and water in and out of cells in various organs
** The approval follows a positive recommendation in April from the European Medicines Agency, the region’s drug regulator
** The FDA approved VRTX's next-generation treatment in December and generated about $53.9 million in sales during Q1
** Including session's move, VRTX up 11.9% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。